Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ALIVUS

ALIVUS

Alivus Life Sciences Limited
Small-capPharma ↗

What the six lenses say about ALIVUS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1388.9
2026-09-08
VWAP · 1Y anchor
₹1058
+31.2% from VWAP
P/E · TTM
—
no TTM EPS
52-week range
91%
position low→high
RSI(14)
58
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How ALIVUS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
8.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD890›

The actual numbers

Price vs VWAP (1y)+31.2%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+26.2%
Price vs 50-EMA+8.8%
RSI(14)58
RS vs Nifty 500 · 3M+34.2%
RS vs sector · 3M+28.1%
52-week range91%
Volume vs 30d avg0.50×
Volume vs 60d avg0.67×
ATR(14) · volatility60.5
Bollinger width · vol contraction0.076
FundamentalD441›

The actual numbers

Return on equity (ROE)18.9%
Operating margin26.1%
Net margin19.4%
Revenue growth · YoY-4.0%
EPS growth · YoY-14.9%
Debt / equity0.00×

Full 8-quarter history in the financials table below.

ValuationD519›

The actual numbers

52-week range91%
CatalystD436›

The actual numbers

Earnings & momentum34
Capital actions12
Governance95

Every filing in the corporate-announcements panel below.

FlowD958›

The actual numbers

Promoter holding74.9%
Delivery · 30d avg49.2%
Up/down-day asymmetry5.5pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D8 + D9 ) ÷ 2 = 8.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
87
Conviction score 87/100 · avg-decile strength 8.5/10
Conviction score87/100›
TechnicalD8›
FundamentalD4›
ValuationD5›
CatalystD4›
FlowD9›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+2.2pp
+0.1pp
+8.3pp
+35.8pp
+54.5pp
+54.9pp
Nifty 500
Broad-market baseline
+2.1pp
+0.1pp
+7.2pp
+34.2pp
+48.8pp
+49.7pp
Sector
Own-sector index
—
—
+4.4pp
+28.1pp
+35.7pp
+28.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ALIVUS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1388.90+22.60

Relative strength

RS vs baseline · rebased to 100

ALIVUS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
116.99+2.39

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

No quarterly financials available.

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 7 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jul '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 30 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 30 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds ALIVUS

Mutual funds holding ALIVUS (10)

FundWeightAUM ₹crGrade
Quant Small Cap Gr0.76%34,069
Quant Flexi Cap Gr1.74%7,262
ICICI Pru Pharma Healthcare Diag Gr1.33%6,803
Helios Small Cap Reg Gr0.79%1,455
Quant Healthcare Reg Gr7.19%397
Bandhan Healthcare Reg Gr1.17%319
Quantum Small Cap Reg Gr2.26%254
Samco Multi Cap Reg Gr0.55%228
Unifi Flexi Cap Reg Gr1.02%227
Navi Aggressive Hybrid Reg Gr0.60%116

ETFs holding ALIVUS (0)

No tracked ETF holds ALIVUS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma